ASCO 2021 | Real-world analysis of Waldenström’s macroglobulinemia treatment and resource utilization in the US
Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the real-world treatment patterns, adherence, costs, and healthcare resource utilization associated with Waldenström’s macroglobulinemia in the US. Frequency and duration of treatment regimen, discontinuation rates, switching rates, costs per-patient-per-month (PPPM), and inpatient, outpatient, and pharmacy visits are discussed. Dr Castillo concludes significant clinical and economic burden is associated with Waldenström’s macroglobulinemia in the US. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Disclosures
Jorge Castillo, MD, has received research funds and/or consulting fees from Abbvie, Beigene, Janssen, Pharmacyclics, Roche and TG Therapeutics.
